13801-51-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-[1,5]naphthyridine-3-carboxylic acid ethyl ester is used as a potential antineoplastic agent for the treatment of cancer. Its antineoplastic properties make it a promising candidate for the development of new cancer therapies.
Used in Immunology Research:
4-HYDROXY-[1,5]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER is also used as an immunomodulating agent in the study and treatment of autoimmune diseases. Its ability to modulate the immune system offers potential benefits in managing conditions where the immune system is overactive or misdirected.
Used in Medicinal Chemistry:
4-Hydroxy-[1,5]naphthyridine-3-carboxylic acid ethyl ester serves as a key intermediate in the synthesis of various pharmaceutical compounds with potential therapeutic applications. Its unique chemical structure allows for the development of new drugs targeting specific biological pathways.

InChI:InChI=1/C11H10N2O3/c1-2-16-11(15)7-6-13-8-4-3-5-12-9(8)10(7)14/h3-6H,2H2,1H3,(H,13,14)

Upstream product

• 101-84-8 diphenylether 
• 92-52-4 biphenyl 
• 14029-71-1 2-(pyridin-3-yl)aminomethylene-malonic acid diethyl ester 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 462-08-8 pyridin-3-ylamine 

Downstream Products

• 4901-93-3 3-carboxy-4-hydroxy-1,5-naphthyridine 
• 5423-54-1 4-hydroxy-1,5-naphthyridine 
• 83067-95-2 4-chloro-1,5-naphthyridine-3-carboxylic acid ethyl ester 
• 92972-61-7 2-phenyl-pyrazolo[4,3-c] [1,5]naphthyridin-3(5H)-one 

Relevant academic research and scientific papers

Pharmaceutical composition for promoting fracture healing, preparation method thereof and application thereof

The invention relates to the technical field of medicines and discloses a pharmaceutical composition for promoting the fracture healing. Structurally speaking, the active ingredient of the pharmaceutical composition has the following structure: (img file = 'DDA0001638481410000011. TIF' wi= '347' he= '319'/) The pharmaceutical composition is mainly used for preparing medicines for promoting fracture healing. As far as action is concern, that medicine has good therapeutic effect on osteoporotic fracture, obviously promotes fracture heal, reduces blood viscosity, and has important promoting effect on osteocyte growth.

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

Platinum complexes of 4-hydoxy-1,5-naphthyridines as emitting dyes

4-Hydoxy-1,5-naphthyridines (HNt) are derivatives of 8-hydroxyquinolines, yet possess a wider HOMO and LUMO band gap than the latter. The cyclometalated complex of platinum(II) with Nt exists in a square planner geometry, and has a high tendency to aggregate in condensedmedia. Such a phenomenon was verified by examining its photo-luminescence spectra in different concentrations. In a dilute solution, it exhibits a yellow phosphorescence centered at 530∑555 nm, yet red-shifted to ∑660 nm in a concentrated solution or in the solid state. This series of compounds can be used as emitting dyes in light-emitting diodes (LED). The LED devices with a configuration ITO/NPB/dye (6%) in CBP/BCP/AlQ3 or TPBI/LiF/Al displayed a yellow to red color, where NPB, CBP, BCP, AlQ3 and TPBI denote 4,4′-bis[N-(1-naphthyl), Nphenylamino] biphenyl, 4,4′-bis(carbazol-9-yl)biphenyl, 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline, tris(8-hydoxyquinolinato) aluminium, and 2,2′,2′-(1,3,5-benzenetriyl)tris(1-phenyl-1H- benzimidazole), respectively. The maximal light intensity exceeds 2.6 × 104 cd/m2 with an external quantum efficiency up to 5.8%.